Investigation of treating chronic fatigue syndrome after COVID with pharmacotherapy (pregabalin) or complex rehabilitation

Prior treatment

• Concurrent treatment with opioids or other antiepileptic drugs (including tramadol, buprenorphine, morphine, oxycodone, gabapentin, duloxetine);

Other illness

• Vital functions disorders;
• Documented hypersensitivity to pregabalin or any of the excipients of the formulation (i.e., lactose);
• Moderate or severe depression during treatment or present during psychiatric evaluation at baseline;

Other

• Pregnant or breastfeeding women;

• The patient correctly gave written informed consent to participate in the study;
• Men or women between the ages of 18 and 65 inclusive at the time of signing the informed consent;
• Patient after a minimum of 6 months from the documented detection of SARS-CoV-2 infection (document confirming the history of the disease, including a positive result of the PCR or antigen test, certificate of convalescence; medical documentation confirming the infection; the condition is also considered fulfilled in the case of documented infection asymptomatic);
• During the screening, the patient meets the criteria for the diagnosis of chronic fatigue syndrome (CFS) according to National Academy of Medicine (2015);
• Women: a) incapable of having children (post-menopausal or child-bearing, subjected to permanent sterilization); (b) of childbearing potential with a negative pregnancy test result at screening and using a highly effective method of contraception throughout the IMP use and for 7 days after the last IMP use.
• The patient agrees to participate in all activities provided for in the study.
• The patient is able to understand the information presented and give informed consent to participate in the study prior to screening.